VALBIOTIS SA: Valbiotis raises awareness of cardiometabolic risks with the Cœur en Jeu prevention campaign

Valbiotis raises awareness of cardiometabolic risks with the
Cœur en Jeu prevention campaign

La Rochelle, March 10, 2026 (5:40 PM CEST) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specialized in cardiometabolic health, is taking action to promote prevention and improve understanding of cardiometabolic risks in women through an awareness campaign launching on March 10, 2026, entitled Cœur en Jeu (Heart on the Line), supported by the Agir pour le Cœur des Femmes Foundation.

Cardiovascular diseases (CVD) are among the leading causes of death in women1. 1 in 2 women over 55 is exposed to a major cardiometabolic risk2. These risks increase during menopause, a period of vulnerability that remains largely under-diagnosed. The campaign illustrates Valbiotis’ commitment to making this reality a major public health concern.

Cardiometabolic Health: An invisible Risk

Cardiometabolic health, at the intersection of heart health and metabolic balance, is a direct reflection of our lifestyles. In today’s world, it is increasingly under strain, particularly among women, whose habits and daily lives have changed significantly. Smoking, sedentary behavior, ultra-processed diets, chronic stress and increasing mental load form a cluster of compounding risk factors. Over time, these imbalances weaken the body, compromise overall health and contribute to the development of cardiovascular disease.

However, this trajectory is not irreversible: 80% of these conditions could be prevented through appropriate prevention and healthier lifestyle habits1. Early warning signs such as high cholesterol, weight gain or persistent fatigue, often appear quietly, long before the disease develops. They become critical during key stages in women’s lives, like menopause.

Inform, Engage, Support: Three Pillars to Take Back Control of Your Health

With the support of the Agir pour le Cœur des Femmes Foundation (https://www.agirpourlecoeurdesfemmes.com/), the Cœur en Jeu campaign places women at the heart of cardiometabolic prevention and promotes a positive, accessible and practical approach to risk reduction.

Designed to address the urgent need for prevention, the campaign is built around three key pillars:

• Improving awareness of the still under-recognized links between hormones and cardiometabolic health
• Raising awareness of the impact of lifestyle habits (sleep, stress, diet and exercise)
• Providing women with practical support to help them take better care of their health

The initiative will be rolled out from March to June, through educational content and inspiring events:

• Talks from healthcare professionals to explain the underlying physiological mechanisms and provide reliable, reassuring medical guidance
• Educational tools (public information booklet, self-assessment quiz, etc.)
• Testimonials from committed public figures (Sophie Kune, Elsa Wolinski, etc.).

Sébastien Peltier, CEO and Co-Founder of Valbiotis, says, “Through the Cœur en Jeu campaign, Valbiotis is reaffirming its commitment to prevention and to improving understanding of cardiometabolic risks. As a laboratory specializing in metabolic health, we have a responsibility to support, inform and raise awareness among both the general public and healthcare professionals and to encourage earlier recognition and action on these major public health issues.” 

The entire campaign is available at www.coeurenjeu.fr and is supported by a large-scale promotional campaign to raise Valbiotis' profile among the general public and healthcare professionals. A launch press conference was held today, bringing together more than 34 journalists from leading media outlets (Les Échos, Le Quotidien du Pharmacien, Doctissimo, Santé Magazine, Top Santé, Version Femina, Elle, Avantages, Marie France, etc.). The campaign is also supported by media partnerships with Doctissimo and Aufeminin, content on social media, initiatives with health influencers, and the distribution of information materials in pharmacies.

Shareholder benefit

20% discount on ValbiotisPRO® and ValbiotisPLUS® products, granted by customer service
(service-client@valbiotis.com) upon presentation of proof of ownership of at least 85 shares

Terms and Conditions: Click here

About Valbiotis

Valbiotis is a French laboratory specializing in the creation and distribution of dietary supplements scientifically tested to maintain health at every stage of life. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis offers a new generation of dietary supplements to support cardio-metabolic balance and well-being, and address everyday health issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers.

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label.  Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com

Contacts

Corporate Communication / Valbiotis

Caroline Lamberti

+ 33 6 77 82 56 88

caroline.lamberti@valbiotis.com

Financial communication / Seitosei.Actifin 

Marianne Py

+33 6 85 52 76 93

marianne.py@seitosei-actifin.com

Press Relations / LJ Com by JIN

Valentine Martin

+33 6 32 29 43 82
v.martin@ljcom.net

Name: Valbiotis
ISIN Code: FR0013254851

Ticker Symbol: ALVAL

EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the Valbiotis Universal Registration Document, filed with the French Financial Markets Regulator (AMF) on April 26, 2023, under number D.23-0347, as well as in its Amendment filed with the AMF on December 11, 2023, under number D.23-0347.A01. These documents are available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis' shares or financial securities in any country.